Poging GOUD - Vrij

SC allows govt to reconsider Vi's AGR dues

Business Standard

|

October 28, 2025

This may open doors for other telcos to seek relief, say legal experts

- BHAVINI MISHRA & GULVEEN AULAKH

The Supreme Court on Monday allowed the Centre to reassess Vodafone Idea's (Vi's) adjusted gross revenue (AGR) dues, holding that any relief to the struggling telecom operator lay within the government's policy domain.

A Bench comprising Chief Justice of India B R Gavai and Justices K Vinod Chandran and Vipul M Pancholi accepted the government's submission that the move was driven by consumer interest and the Centre’s substantial equity in India’s third-largest telecom provider.

Solicitor General Tushar Mehta, appearing for the government, told the court that the Centre now holds a 49 per cent stake in Vi. The review, he said, had been prompted by concerns about the firm’s large user base. As of September 2025, Vi had 202.8 million subscribers, according to data from the Trai released on Monday. “We clarify that this falls within the Union’s policy domain, and there is no reason to prevent the government from proceeding accordingly,” observed the Bench, disposing of the matter.

Senior advocate Mukul Rohatgi, representing Vi, expressed satisfaction with the government's approach.

Taking note of the government's equity infusion and the potential impact on millions of users, the court said: "Taking into consideration the status of the case now, the government has infused substantial equity into the company, and further, that the issue involved is likely to have a direct bearing on the interests of 20 crore customers, we see no issue in the Union reconsidering the issue and taking an appropriate decision." The Bench stressed that its order was confined to the specific facts of the case, particularly the central government's stake in the company and its stated aim of protecting consumer interests. A detailed order is awaited.

MEER VERHALEN VAN Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size